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 ABSTRACT                                                                                                                                            
A Study of the androgen receptor gene polymorphism 
and the level of expression of the androgen receptor in 
androgenetic alopecia among Egyptians
Heba SH. Kassem1,2, Rehab M. Abou El Seoud3, Adel SH. Aly3, Hala A. Ibrahim3 
and Mahmoud A. El Ramly3.
1Pathology Department, 2Clinical Genomics Centre, 3Dermatology and 
Venereology Department, Faculty of Medicine, Alexandria University, Egypt
Background: Androgenetic alopecia (AGA) occurs in men and women. The 
nature of the genetic predisposition to androgenetic alopecia is still unresolved. 
The aim of the work is to study the genotype of the androgen receptor gene 
(StuI polymorphism) and its relationship to AGA in a case control study and to 
determine the level of androgen receptor expression (AR) in the balding scalp 
relative to the non-balding scalp area.
Subjects and Methods: This study was conducted on one hundred individu-
als; 60 cases with AGA (36 males and 24 females) and 40 age and sex matched 
control patients (20 males and 20 females). StuI restriction fragment length 
polymorphism(RFLP) of exon 1 was detected by PCR based assay using ge-
nomic DNA of subjects with AGA and controls. Immunohistochemical detec-
tion of the androgen receptor (AR) using antihuman AR antibody was imple-
mented to compare its level in the balding scalp and in the non-balding area in 
individuals having AGA.
Results: Analysis of StuI restriction fragment length polymorphism in exon 1 
of the androgen receptor (AR) gene revealed a relatively commoner incidence 
of the cut allele in males with AGA relative to age and sex matched controls 
(the association was of border line signifi cance p=0.07. Interestingly, all per-
sons who had maternal uncles suffering from AGA had the Stu1 cut variant of 
AR gene (p= 0.03 using Chi square test). Semiquantitative immunohistochemi-
cal analysis of AR in the bold scalp biopsies showed higher expression in the 
level of AR than the non bold bioposies within the same individual.
Conclusion: To the best of our knowledge this is the fi rst study of AR gene pol-
ymorphism and AR expression in AGA amongst Egyptians. This study contrib-
utes in the understanding of the molecular pathogenesis of AGA which could 
help in fi nding better therapeutic alternatives for such trait in the future.




Androgenetic alopecia, androgen re-
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INTRODUCTION                                        
Androgenetic alopecia (AGA) is the 
most common cause of hair loss in both 
men and women. In men, it is often 
referred to as male-pattern baldness; a 
common form of scalp hair loss that af-
fects most males by old age1. The con-
dition can also affect females; however, 
this is less well characterized and it re-
mains controversial as to whether the 
two conditions are the same. Certain-
ly, the pattern of hair loss is different 
in women and the prevalence is lower 
than that in men.2
The onset of AGA is extremely vari-
able and appears to be determined by 
the presence of suffi cient circulating 
androgens and the degree of genetic 
predisposition. The condition is not a 
serious one from a medical perspective; 
however, the loss of hair is often an un-
wanted and stressful for the patient and 
therefore might have considerable psy-
chosocial consequences.3 
Male pattern hair loss usually follows 
a defi ned pattern, as described by the 
Hamilton–Norwood scale. Women; on 
the other hand, have lesser degrees of 
miniaturization of terminal hairs in af-
fected areas and therefore, rarely any 
‘balding’ when compared to men. Fe-
male pattern hair loss (FPHL) is not as 
easily classifi able as in men; three dif-
ferent clinical patterns have been de-
scribed: The Ludwig pattern, the Ham-
ilton pattern and the Christmas tree pat-
tern4. Most commonly FPHL presents 
by the Ludwig’s pattern.4
Androgenetic alopecia is the result of 
step-wise miniaturisation of the hair 
follicle and alteration of the hair-cycle 
dynamics5. Pre-programmed follicles 
on the scalp progress through long 
growth (anagen) cycles and short rest 
(telogen) cycles. With each passage 
through the hair cycle, the duration of 
the anagen phase decreases whereas the 
telogen phase elongates. By time, the 
length of the new anagen hair becomes 
considerably shorter than that of its pre-
decessor and the emerging hair does not 
reach the skin. In addition, the latency 
period between telogen hair shedding 
and anagen regrowth becomes longer, 
leading to a reduction in the number of 
hairs present on the scalp.5
Interestingly, the hair follicle may fol-
low an alternative route during which 
the telogen phase, not accompanied by 
a coincident new early anagen, ends 
with teloptosis leaving the follicle emp-
ty6. Kenogen indicates the physiologi-
cal interval of the hair cycle in which 
the hair follicle remains empty after the 
telogen hair has been extruded and be-
fore a new anagen hair emerges. Keno-
gen frequency and duration are greater 
in men and women with androgenetic 
alopecia (AGA).7
The follicular miniaturization that ac-
companies these hair-cycle changes is 
global, affecting the papilla, the matrix 
and ultimately the hair shaft. The der-
mal papilla is fundamental to the main-
tenance of hair growth and is probably 
the target for androgen-directed apop-
tosis or cell migration8. It is generally 
believed that there is only one androgen 
receptor because of the wide- ranging 
effects throughout the body with the ab-
sence of functional androgen receptors 
in testicular feminization and the results 
of cloning studies of the androgen re-
ceptor9. The concentration of androgen 
receptors, however, was signifi cantly 
higher in dermal papilla cells derived 
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from the androgen- dependent follicles 
including beard, moustache, pubis and 
scrotum than in the relatively andro-
gen- insensitive areas of ‘non- balding’ 
scalp.10
The androgen receptor (AR) is a typical 
steroid receptor and is responsible for 
determining the sensitivity of cells to 
androgens. The human AR gene local-
izes to the X chromosome at Xq11–12 
and is encoded in 8 exons. The steroid 
hormone receptors regulate gene tran-
scription by interacting with a specifi c 
DNA sequence in a ligand-dependent 
manner.11
The distribution of androgenetic alope-
cia has been found to follow a normal 
distribution, representing the full range 
of phenotypes, from no evidence of hair 
loss, to fully developed baldness. This 
distribution is more consistent with a 
polygenic trait. In addition, it is worth 
noting that hereditary traits determined 
by a single gene rarely occur at a fre-
quency greater than 1 in 1000. Although 
the exact frequency of AGA is diffi cult 
to ascertain, it has been estimated to be 
between 40% and 60% in men, further 
supporting a more pervasive mode of 
inheritance.12
The sequences of several candidate 
genes for androgenetic alopecia were 
studied because of their relevance to 
the hypothesis that androgens are in-
volved in this form of hair loss. Among 
these were the genes that encode the 
5α-reductase enzymes: SRD5A1 and 
SRD5A2, in male-pattern baldness be-
cause 5α-reductase converts testoster-
one to DHT. However, analysis of these 
genes using case–control and familial 
linkage studies have shown that it is un-
likely that they contribute to androge-
netic alopecia13,14. Also, the autosomal 
gene encoding aromatase cytochrome 
P450 gene, CYP19, was compared be-
tween cases and controls but no differ-
ence was detected, suggesting that it is 
unlikely that the aromatase gene is in-
volved in determining predisposition to 
androgenetic alopecia.15 
Following the same trail, the observed 
father-to-son transmission of AGA 
raised the hypothesis that a gene on the 
Y chromosome might contribute to the 
condition. In addition, the Y chromo-
some determines sex and the concentra-
tions of sex steroids such as testoster-
one and DHT16. However, examination 
of the non-recombining region of the Y 
chromosome has demonstrated that it is 
unlikely that causative mutations occur 
in any genes contained in this region.15
Owing to the fact that an increased con-
centration of androgen receptor is asso-
ciated with the balding scalp17, differ-
ences in the DNA sequence of the gene 
encoding the androgen receptor, or in 
the AR regulatory sequences, might 
lead to differences in the concentration 
or activity of the receptor. Such differ-
ences might increase sensitivity to DHT 
in balding individuals, leading to hair 
loss at an earlier age.
The frequency of short AR repeat 
lengths of both CAG and GGC has 
been found to be signifi cantly greater in 
young bald men than in non-bald men. 
The ubiquity of the androgen receptor 
gene StuI restriction site and higher 
incidence of shorter triplet repeat hap-
lotypes in bald men suggests that these 
markers are very close to a functional 
variant that is a necessary component 
of the polygenic determination of male 
pattern baldness.
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Functional mutation in or near the an-
drogen receptor gene may explain the 
reported high levels of expression of 
this gene in the balding scalp.18
In addition to androgen-related genes, 
genes that are involved in patterning, 
signalling and hair-follicle morphogen-
esis are attracting much attention from 
researchers. Important candidate areas 
include fi broblast growth factor, WNT 
(wingless type) proteins, β-catenin, 
LEF1, FOXN1 (forkhead box N1), nog-
gin, bone morphogenic protein 2 and 4, 
sonic hedgehog and its cognate receptor 
patched, platelet-derived growth fac-
tor A, follistatin and epidermal growth 
factor.19
Without treatment, androgenetic alo-
pecia is a progressive condition. Hairs 
decrease in number at a rate of ~5% per 
year20. Apart from various camoufl age 
and surgical options, there are a num-
ber of topical and systemic drugs, in-
dividually or combined, which may be 
used for treating the condition21. These 
include some over the counter (OTC) 
products e.g. Serenoa Repens (Saw Pal-
metto ) Permixon; a naturally occurring 
5 alpha reductase inhibitor22 and zinc in 
specifi c forms (i.e., zinc acetate, zinc 
sulfate) which limits the reduced cofac-
tor NADPH of 5a-R that is necessary for 
the 5a reduction of testosterone to form 
DHT23. Nutrients that are promoted by 
health food stores to ‘help hair grow’ 
include the amino acids Arginine/L-
arginine and/or cysteine / cysteine/L-
Cysteine, biotin and folic acid24. Pre-
scription drugs include, Spironolactone, 
an aldosterone antagonist that acts as a 
weak antiandrogen in blocking the AR, 
but also inhibits androgen biosynthesis. 
Cyproterone acetate, is another well-
known antiandrogen that can be used 
in female AGA, hirsutism and viriliz-
ing syndromes25. Additionally, there is 
oral fi nasteride which has been shown 
to be effective in the treatment of hair 
loss in men, while its effi cacy in women 
has remained controversial26. It is a po-
tent and highly selective 5α-reductase 
type-2 inhibitor27. It binds irreversibly 
to the 5α-reductase type-2 enzyme and 
inhibits the conversion of testosterone 
to DHT. Topical formulations include 
Minoxidil which appears to prolong the 
anagen growth phase leading to a de-
crease in hair shedding, but it does not 
inhibit the biological process. Hence, 
once treatment is stopped, hair shed-
ding rapidly resumes, with the loss of 
all minoxidil-stimulated hair growth.28
Failure of any of these agents to per-
manently reverse the hair loss process 
has led to the introduction of innova-
tive modalities in this fi eld. Namely, 
gene therapy29,30, antisense chimeras31, 
growth factors32,33 and stem cell34 tech-
nologies are among those researched 
for such purpose.
SUBJECTS AND METHODS                            
This study included 60 cases having an-
drogenetic alopecia (AGA): 36 males 
and 24 females, who came to the Der-
matology Department Outpatient Clinic 
of Alexandria University Main Hospital 
and forty volunteer control participants 
(20 males and 20 females) were also in-
cluded. All cases of AGA were subject-
ed to thorough history taking and clini-
cal examination to determine the type 
and grade of alopecia and 4mm punch 
biopsies were taken from both the bald 
and the non-bald scalp areas. Informed 
consent was obtained from the partici-
pants following the explanation of the 
details of the procedures to them. Blood 
samples were collected from both the 
patients and controls. Additionally, 
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family history of close relatives with 
apparent advanced grades of hair loss 
was collected from the patients. Ap-
proval was obtained from the Research 
Review Committee of Alexandria Fac-
ulty of Medicine prior to undertaking 
the study.
I- Detection of StuI RFLP of exon 1 
of AR gene:
Blood samples (1-2ml whole blood) 
were collected in EDTA tubes. The 
“Qiagen DNA Mini Kit” was used for 
the genomic DNA extraction, following 
the instruction of the manufacteurer. 
PCR amplifi cation of a region in exon 
1 of AR gene containing the polymor-
phism for StuI restriction endonuclease 
enzyme was undertaken in a 25μl reac-
tion using 10 picomoles of the prim-
ers (F 5’-CACAGGCTACCTGGTC-
CTGG-3) and (R5’-CTGCCTTACA-
CAACTCCTTGGC-3’)35. The PCR 
amplifi cation of a 416 bp fragment of 
exon 1 of AR gene was detected. The 
reaction mixture for the amplifi cation 
procedures was prepared in a fi nal vol-
ume of 25μl using the PCR core system 
I PCR (Amersham Biosciences). The 
amplifi ed products were digested with 
StuI restriction endonuclease (5units per 
reaction in the presence of 1x buffer B) 
following the manufacturer instructions 
(Fermentos). The products were elec-
trophoresed through agarose 2% gels 
and stained with ethidium bromide.
II-Histological examination of scalp 
biopsies:
Four millimetre punch biopsies were 
taken from the occipital non- balding 
area (labelled as A) and three and a half 
millimetre punch biopsies were taken 
from the balding scalp area of the same 
patient (labelled as B) of sixty cases 
with AGA (36 males and 24 females). 
They were immediately fi xed in buff-
ered formalin saline and were processed 
and stained with routine H&E stain and 
examined microscopically for:
 -The presence of intact hair follicles 
in biopsies taken from the non-bald 
area ‘A’.
 -The presence of miniaturized hair fol-
licles in biopsies taken from the scalp 
area of Androgenetic alopecia ‘B’.
III- Immunohistochemical detection 
of the androgen receptor:
The level of expression of the androgen 
receptor in the skin of the scalp was de-
tected using the Avidin-Biotin indirect 
immunoperoxidase method36. Sections 
A (from the non-bald scalp area) were 
compared to sections B (from the bald 
area). The slides were scored indepen-
dently by two examiners and an average 
semi-quantitative score was determined 
for each section. Sections were scored 
as Negative, 1+, 2+ or 3+ depending on 
the staining intensity and the proportion 
of positive cells. Negative (N) if < 10% 
of nuclei were immunoreactive, mild 
(1+) if 10-25% of nuclei were positive, 
moderate (2+) if 25-50% of nuclei were 
positive and strong (3+) if > 50% of nu-
clei were positive.
Negative control section was included 
on each slide, in which the primary 
antibody was replaced by phosphate 
buffered saline (PBS). A pap pen was 
used to avoid overfl ow of the Ab to the 
negative section. Slides of Senile pros-
tatic hyperplasia were used as a positive 
control in each run. Sebaceous glands 
were found to be positive in all studied 
biopsies, thus it was considered as an 
internal positive control.
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IV-Statistical analysis:                                   
Androgen receptor StuI polymorphism 
association in the case control study 
was analysed using Chi square and im-
munohistochemical analysis of AR ex-
pression was studied using Wilcoxon 
signed rank test and Mann Whitney U 
test. Statistical signifi cance level was 
considered at p≤0.05.
RESULTS                                                             
This study included 60 cases having 
AGA (36 males and 24 females) who 
sought medical advice at the Dermatol-
ogy Department Outpatient Clinic of 
Faculty of Medicine, Alexandria Uni-
versity Main hospital. Forty control 
participants (20 males and 20 females) 
were also included in the study. The 
age of the patients, in the study Group, 
ranged between 16 and 58 years, with 
a mean age of (29.27 ± 10.58). The 
controls were chosen to be age and sex 
matched. Their ages varied from 18-50 
with a mean age of (29.8 ±8.33). Grades 
of AGA according to the Hamilton-Nor-
wood classifi cation ranged from frontal 
alopecia (grades II & III), frontal hair 
loss and temporal recession (grades 
IV & V) and total frontal and vertex 
alopecia (grades VI &VII). In males, 
58.3% (21/36) of patients had frontal 
baldness of gradeIII, 30.6% (11/36) 
had gradeV, and 11.1% (4/36) had total 
frontal and vertex baldness of gradeVII 
AGA. An additional classifi cation; the 
Ludwig FPHL was employed for the 
females37. Ludwig (I) pattern hair loss 
was obvious in 16.7% (4/24) of the fe-
male patients, 75% (18/24) had L (II) 
FPHL. and 8.3% (2/24) of the females 
had L (III) FPHL.
Immunohistochemical analysis of AR 
expression:
Tissue samples taken from the bald 
area (Group B) showed higher per-
centage of androgen receptor (AR) 
expression than those taken from the 
non-bald region (Group A). The dermal 
papilla (DP) was the main part of the 
hair follicle showing the characteristic 
nuclear staining indicating the pres-
ence of AR (Figure. 1). It was observed 
that DP in sections taken from Group 
B (bald area) stained more intensely 
indicating a higher expression of AR 
(Figure. 1A) in comparison to the less-
intense staining observed in non-bald 
areas indicating less number of AR in 
DP nuclei (Figure. 1B).
Semiquantitative screening of AR 
immunostaining scoring of scalp bi-
opsies showed 3.3% (2/60) of cases 
from Group A with negative staining 
of the epidermis while none of Group 
B was negative. Whilst AR staining 
was scored as mild in 80 % ( 48/60) of 
cases in Group A, only 25% (15/60) of 
cases of Group B showed mild staining. 
Moderate staining was observed in 55% 
(33/60) of cases in Group B compared 
to only 15% (9/60) of cases in Group 
A. Additionally, 20% (12/60) of cases 
from Group B showed strong nuclear 
staining whereas only 1.7% (1/60) in 
Group A revealed strong staining. The 
difference between the intensity of 
nuclear staining in the two Groups was 
statistically highly signifi cant P<0.0001 




Fig. 1: Androgen Receptor (AR) Immunostaining In Scalp Biopsies. (Figure A)Bald scalp AR immu-
nostained biopsy showing strong positive staining of nuclei of hair follicle dermal papilla(DP). (B) Non 
bald scalp biopsy of the same individual showing less intense staining of AR of the hair follicle DP. 
(Magnifi cation is 400x).
Table 1: Comparison of intensity of nuclear staining between non bald and bald scalp tissue 
sections.
Group A





Negative 2(3.3) - 2(1.67)
1+ (mild) 48 (80) 15(25) 63(52.5)
2+ (moderate) 9(15) 33(55) 42(35)
3+ (strong) 1(1.7) 12 (20) 13 (10.83)
Total 60(100) 60(100) 120(100)
WSRT -6.13
P value < 0.001*
*Statistically signifi cant at P≤ 0.05.
PCR based analysis of StuI polymor-
phism of exon 1 of AR gene:
Sixty patients (36 males and 24 females) 
and forty control patients (20 males and 
20 females) were included in the study. 
However, 9 cases and 3 controls were 
excluded due to poor quality of the 
sample which resulted in inhibition of 
the PCR.
PCR amplifi cation of a region in exon 1 
of AR gene was performed followed by 
detection of the polymorphism for StuI 
restriction endonuclease enzyme.
The AGGCCT sequence is cut by the 
StuI restriction enzyme resulting in 
329/87bp (cut allele), while the AGAC-
CT sequence is not digested by StuI, 
resulting in a 416bp fragment. The 
StuI restriction site in the AR gene, is 
located on the Xq12.22 chromosome. 
Consequently, male participants are 
hemizygous for the AR gene polymor-
phism. Females, however, presented 
with either a heterozygous state with 
two bands appearing; one at 416bp 
and another at 329bp or with a homo-
cut state with only the 329bp & 87bp 
(Figure. 2).
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Fig. 2: Gel captured image of the StuI Restriction assay using 2% agarose gel electrophoresis. The AGGCCT 
sequence is cut by the StuI restriction enzyme, while the AGACCT sequence is not. Lane1: Undigested 
sample (band size = 416bp). Lanes 2,4,5,6,10 show two bands one at 416bp and another at 329bp indicating 
a heterozygous state (female cases). Lanes 3,7,8,9,11,12,13 show a transluminant band at 329bp indicating 
it is homo- cut by the StuI restriction enzyme Lane 14 shows a transluminant band at 416bp indicating it is 
homo-uncut. M: 100bp DNA marker.
Among the cases studied, 11.8% (6/51) 
were homo uncut indicating absence 
of the ‘cut’ allele compared to 29.7% 
(11/37) of the control Group. Whereas 
66.7% (34/51) of the alopecic patients 
were homo-cut, 48.6% (18/37) of the 
controls. In females having FPHL, 
21.6% (11/51) were heterozygous simi-
lar to the percentage of heterozygous 
alleles detected among the control fe-
males, (21.6%, 8/37).
The cases were sub-stratifi ed according 
to the gender and the analysis was re-
peated. As regards the males included 
in the study (Table 2), 12.9% (4/31) 
of the alopecic males did not inherit 
the cut allele compared to 38.9% (7/18) 
of the control males. On the other 
hand, 87.1% (27/31) of the males hav-
ing AGA had the cut allele compared 
to only 61.1% (11/18) of those of the 
control Group. This association be-
tween the AR StuI polymorphism and 
occurrence of AGA was found to be of 




Table 2: Comparison of genotype between cases and controls in males.
Bald N (%)  Control N (%) Total N (%)
Home uncut 4(12.9) 7(38.9) 11 (22.4)
Home cut 27(87.1) 11 (61.1) 38(77.6)
Total 31(100) 18(100) 49(100)
P value of fi sher exact test            0.07
Regarding the results of the genotype 
analysis in females (Table 3), it was ob-
served that 10% (2/20) of the patients 
did not inherit the uncut allele com-
pared to 21.1% (4/19) of the control. 
Thirty fi ve percent (7/20) of the patients 
and 36.8% (7/19) of those not suffering 
of FPHL were homo-cut. Out of those 
who were heterozygous, 55% (11/20) 
had FPHL and 42.1% (8/19) had no hair 
loss. To conclude, the association be-
tween the AR StuI polymorphism and 
the occurrence of FPHL in the female 
cohort was not statistically signifi cant 
(p= 0.57 using Chi square test).
Bald N (%) Control N (%) Total N (%)
Home uncut 2(10) 4(21.1) 6(15.4)
Home cut 7(35) 7(36.8) 14(35.9)
Hetero cut 11(55) 8(42.1) 19 (48.7)
Total 20(100) 19 (100) 39 (100)
Chi square               1.12
P Value               0.57
Table 3: Comparison of genotype between cases and controls in females.
All clinicopathologic parameters were 
included in the multinomial logistic 
regression model which showed no 
relation between the age of the pa-
tient and the corresponding genotype 
(p value=0.661). The grade of alopecia 
with which a case presented, was sig-
nifi cantly related to the genotype of the 
patient (p value= 0.002).
There was a signifi cant relationship 
detected between the presence of fam-
ily history of an affected close rela-
tive and the genotype of the individual 
(p value <0.0001).
Relationship between the level of 
expression of AR in the bald and the 
presence of AR polymorphism:
The level of expression of AR in the 
bald tissue sections of patients and the 
results of the PCR based analysis of 
StuI polymorphic site in exon 1 of the 
AR were undertaken blindly. Studying 
the relationship between the expression 
and the StuI AR polymorphism showed 
a signifi cant relation (p=0.05 using Chi 
square test). Statistical analysis of our 
data revealed a signifi cant level of AR 
detected in the bald scalp biopsies in 
patients having the ‘cut’ allele. Among 
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those demonstrating mild nuclear stain-
ing for the presence of the androgen 
receptor, 30% (3/10) did not have the 
“cut” allele, 30% (3/10) were homo-
cut and 40% (4/10) were heterozygous. 
Regarding those in which moderate 
staining was observed, 3.4% (1/29) 
Table 4: Relation between genotype and intensity of nuclear staining in bald scalp tissue 
sections.
were uncut compared to 72.4% (21/29) 
homo-cut individuals and 24.2% (7/29) 
heterozygous ones. Those who were 
observed to have strong nuclear inten-
sity, 75% (9/12) were homo-cut, 16.7% 












Home uncut - 3(30%) 1(3.4%) 2(16.7%) 6(11.8)
Home cut - 3(30%) 21(72.4%) 9(75%) 33(64.7)
Hetero cut - 4(40%) 7(24.2%) 1(8.3%) 12 (23.5)
Total - 10(100%) 29(100%) 12(100%) 51(100)
Chi square        9.44
P Value        0.05*
DISCUSSION                                                
The common heritable loss of scalp hair 
known as male pattern baldness or An-
drogenetic alopecia affects up to 80% 
of males by age 80 years. According to 
Hamilton38, the hair loss is heriTable, 
androgen dependent and occurs in a de-
fi ned pattern. Ellis et al.13 showed that 
the mode of inheritance remains un-
proven; however, it is most likely poly-
genic.
Studies were conducted on cultured 
dermal papillae derived from various 
parts of the human body to unravel the 
paradoxical responses of hair follicles 
to androgens10,39,40. This was done in 
the hope for fi nding better therapeutic 
modalities for androgen dependent dis-
orders such as hirsutism and AGA10. 
Randall et al.10 observed that cultured 
dermal papilla cells from androgen-
dependent human hair follicles (e.g. 
beard) contain more androgen recep-
tors than those from non-balding areas 
of the scalp. However, Hibberts et al.40  
reported that the expression of the an-
drogen receptor is increased in balding 
scalp. This is in agreement with our 
study in which the scalp biopsy ob-
tained from the bald area demonstrated 
a signifi cantly higher level of expres-
sion of the AR in comparison to the non 
bald scalp biopsy.
On the other hand, Sinclair1 has stated 
that since drugs such as fi nasteride, 
which inhibit the formation of the po-
tent androgen DHT, have shown to re-
verse baldness in affected individuals, 
then tissue-specifi c abnormalities of the 
androgen receptor are not suffi cient to 
cause baldness. This indicates that both 
high androgen levels and increased an-
drogen receptor expression are required 
to cause baldness. Ellis et al.18 pointed 
out that this could probably be attributed 
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to the polygenic nature of androgenetic 
alopecia. In fact, this could be a likely 
explanation to what has been found in 
our study. There was a borderline sig-
nifi cant relationship detected between 
the grade of alopecia and the level of 
expression of AR in males. To the best 
of our knowledge, this is the fi rst study 
to suggest possible correlation between 
the grade of AGA in males and the level 
of expression of the AR in the balding 
scalp; a point which is worth further 
study.
Accordingly, the tissue-specifi c dis-
tribution of the AR raises the possi-
bility of functional mutations in the 
upstream promoter regions of its gene 
that causes increased transcription and 
translation in the affected scalp18. Ellis 
et al.18 conducted a study on Australian 
males recruited from a ‘Victorian Fam-
ily Heart Study, in which the StuI RFLP 
marker was investigated to determine 
the link between AR gene and AGA18. 
This StuI restriction site is located in 
the fi rst exon of the gene and is caused 
by a single third base change, Adenine 
(A) to Guanine (G), that does not cause 
an amino acid change. It was reported 
that a genetic mutation in or near AR 
could be in linkage disequilibrium with 
the StuI restriction site (i.e. the two al-
leles are found together along genera-
tions without cross-over) is a possible 
explanation. The relationship between 
AR StuI polymorphism and AGA was 
further documented by Levy-Nissen-
baum et al.41, in Israeli males having 
AGA. Hillmer et al.42 observed associa-
tion between severe form of AGA and 
AR Stu1 polymorphism in patients of 
German descent, but the relationship 
did not reach statistical signifi cance. In 
the present study, the StuI restriction 
site was commonly observed among 
the bald, suggesting a possible asso-
ciation between the polymorphic site 
in the AR gene and the occurrence of 
Androgenetic alopecia, however an ap-
preciable number of the non-bald par-
ticipants also had this variant, therefore, 
additional genes and factors are likely 
to play additional role.
AR StuI polymorphism was also studied 
in females complaining of AGA in the 
present study, this restriction site has not 
been previously investigated in females 
having AGA, however no statistically 
signifi cant relationship was observed. 
It is a fact that neither the androgen-
dependent nature nor the genetic basis 
of female pattern hair loss (FPHL) has 
been clearly established43. Concerning 
the investigation of AR polymorphism 
in females with AGA, it is rather diffi -
cult to make concrete assumptions. AR 
mutations in females at the StuI restric-
tion site were designated as being either 
homozygous or heterozygous. It is true 
that in female mammals, most genes 
on one X chromosome are silenced as 
a result of X-chromosome inactivation. 
However, some genes escape X-inac-
tivation and are expressed from both 
the active and inactive X chromosome. 
Such genes are potential contributors to 
phenotypic variability among females 
heterozygous for X-linked conditions.44
A signifi cant relationship between the 
grade of alopecia and the detection of 
StuI polymorphic site in exon1 of the 
AR gene, was found in both the males 
and the females. In other words, individ-
uals inheriting the cut allele had higher 
grades of alopecia. Our study is the fi rst 
to prove such a correlation in either the 
males or the females. Therefore, in-
heritance of the StuI polymorphic allele 
has an additional impact on the degree 
of hair loss and thereby, the grade of 
AGA with which a case presents. This 
fact applies to both males in which the 
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Hamilton-Norwood classifi cation of 
AGA is employed and to females with 
the Ludwig pattern of FPHL.
In an attempt to underline the fact 
that a strong family history predis-
poses to early development and rapid 
progression of AGA as proposed by 
Tosti et al.4, family history was collected 
from patients included in this study. Al-
most all of the cases who had maternal 
uncles suffering from advanced stages 
of AGA were found to have homo-cut 
genotype at the AR StuI polymorphism. 
Also, the majority of males having only 
their father suffering from high grade 
AGA had inherited the allele. A signifi -
cant correlation was found between the 
family history of having a relative (fa-
ther or maternal uncle) with AGA and 
the presence of the cut allele. Therefore, 
it still remains to be explained why fa-
thers and sons tend to have the same 
pattern of alopecia. A likely explanation 
would be that the remaining etiological 
fraction is due to other genetic variation 
at autosomal loci. Half of the women 
who had an affected mother were homo-
cut and ~40% were heterozygous. From 
this, it becomes quite apparent that this 
polymorphic site of the AR ranks high 
among the essential factors which is 
inherited from the maternal side of the 
family and possesses a strong infl uence 
on the expression of this disease.
Our study has shown a signifi cant as-
sociation between the level of expres-
sion of AR and the presence of AR 
StuI polymorphism in both males and 
females. It was observed that patients 
having AR gene polymorphism at the 
StuI restriction site of exon 1 tend to 
have higher expression levels of AR in 
their balding scalp tissue. To the best of 
our knowledge, this study is the fi rst to 
report such an association. Further stud-
ies on the genetic factors involved in 
AGA are warranted to establish geno-
type phenotype correlation and to pave 
the road to new treatment modalities. 
Though the development of a cream 
that could permanently restrict andro-
gen receptor expression within the hair 
follicle is some years away, research 
is currently focusing in that direction. 
This provides another application to the 
fi nding of higher expression of AR in 
the balding scalp in comparison to that 
in the non-bald area. In the mean time, 
supporting the patients emotionally and 
ensuring that they understand the limi-
tations of the currently available treat-
ments, remain to be the only options in 
the management of AGA.1
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